Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-Current Assets: 2022-2025

Historic Non-Current Assets for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $16.6 million.

  • Taysha Gene Therapies' Non-Current Assets fell 11.03% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year decrease of 11.03%. This contributed to the annual value of $18.2 million for FY2024, which is 20.25% down from last year.
  • As of Q3 2025, Taysha Gene Therapies' Non-Current Assets stood at $16.6 million, which was down 2.72% from $17.1 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Non-Current Assets ranged from a high of $68.5 million in Q3 2022 and a low of $16.6 million during Q3 2025.
  • Its 3-year average for Non-Current Assets is $21.5 million, with a median of $21.9 million in 2024.
  • Data for Taysha Gene Therapies' Non-Current Assets shows a maximum YoY crashed of 65.00% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Non-Current Assets stood at $29.9 million in 2022, then declined by 23.43% to $22.9 million in 2023, then declined by 20.25% to $18.2 million in 2024, then decreased by 11.03% to $16.6 million in 2025.
  • Its Non-Current Assets stands at $16.6 million for Q3 2025, versus $17.1 million for Q2 2025 and $17.7 million for Q1 2025.